Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 3/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | MMP12 | P39900 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 4/20 | 0.59 |
| ▸ | CA1 | P00915 | 3/20 | 0.59 |
| ▸ | MMP2 | P08253 | 2/20 | 0.59 |
| ▸ | MMP9 | P14780 | 2/20 | 0.59 |
| ▸ | MMP13 | P45452 | 2/20 | 0.59 |
| ▸ | MMP8 | P22894 | 1/20 | 0.59 |
| ▸ | MMP3 | P08254 | 1/20 | 0.58 |
| ▸ | MMP7 | P09237 | 1/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | CA3 | P07451 | 1/20 | 0.54 |
| ▸ | CA4 | P22748 | 1/20 | 0.54 |
| ▸ | CA6 | P23280 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4832452 | 0.87 | MMP9 (0.61) | GAACA2CA1MMP9MEN1 | |
| SCHEMBL1665568 | 0.85 | CA1 (0.57) | MMP1CA2CA1MMP2MMP9 | |
| SCHEMBL8121548 | 0.84 | ALDH1A1 (0.59) | MMP1GAACA2CA1MMP2 | |
| SCHEMBL22492554 | 0.83 | GAA (0.66) | MMP1GAACA2CA1MMP2 | |
| SCHEMBL7526085 | 0.80 | CA2 (0.63) | MMP1GAACA2CA1MMP2 | |
| SCHEMBL25340071 | 0.80 | MEN1 (0.62) | MMP1GAACA2CA1MMP2 | |
| SCHEMBL22492367 | 0.79 | ALDH1A1 (0.60) | MMP1GAACA2CA1MMP2 | |
| SCHEMBL9871845 | 0.79 | ALDH1A1 (0.69) | GAAMEN1KMT2AALDH1A1 | |
| SCHEMBL359770 | 0.78 | MMP1 (0.79) | MMP1GAAMMP12MMP2MMP9 | |
| SCHEMBL5097888 | 0.78 | RAB9A (0.49) | MMP1GAACA2CA1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289810-A1 | Compounds As NLRP3 Inflammasome Inhibitors And Their Use As Medicaments | MAM-AGE S.R.L. (IT) | 2025-09-18 | — | — | US | disclosed |
| WO-2023209109-A1 | COMPOUNDS AS NLRP3 INFLAMMASOME INHIBITORS AND THEIR USE AS MEDICAMENTS | MAM - AGE S.R.L. (IT) | 2023-11-02 | — | — | WO | disclosed |
| WO-2017158147-A1 | PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2017-09-21 | — | — | WO | disclosed |
| US-20170240519-A1 | BENZOFURAN ANALOGUE AS NS4B INHIBITOR | CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD. (CN) | 2017-08-24 | — | — | US | disclosed |
| EP-3199530-A1 | BENZOFURAN ANALOGUE AS NS4B INHIBITOR | Changzhou Yinsheng Pharmaceutical Co., Ltd. (CN) | 2017-08-02 | — | — | EP | disclosed |
| US-20160046590-A1 | SONIC HEDGEHOG MODULATORS | MASSACHUSETTS INST TECHNOLOGY (US) | 2016-02-18 | — | — | US | disclosed |
| WO-2011097491-A1 | BENZIMIDAZOLE ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2011-08-11 | — | — | WO | disclosed |
| WO-2011050284-A1 | PYRAZOLYLPYRIDINE ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011041713-A2 | PIPERAZINYL ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2011-04-07 | — | — | WO | disclosed |
| US-7879808-B2 | potent activity against resistant pneumococci; for treating domestic fowl | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2010-08-19 | — | — | US | disclosed |
| EP-2151447-A1 | LINCOMYCIN DERIVATIVES AND ANTIBACTERIAL AGENTS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | Meiji Seika Kaisha Ltd. (JP) | 2010-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240519-A1 | BENZOFURAN ANALOGUE AS NS4B INHIBITOR | GTF3C4, BRD4, CUL4B | MMP1 3966/4885GAA 2466/4885MMP12 3733/4885 |
| US-20250289810-A1 | Compounds As NLRP3 Inflammasome Inhibitors And Their Use As Medicaments | NLRP3, NLRP1, IL18 | MMP1 381/4885GAA 4577/4885MMP12 452/4885 |
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | LAS1L, LCLAT1, LYPLA1 | MMP1 982/4885GAA 2645/4885MMP12 1219/4885 |
| US-20160046590-A1 | SONIC HEDGEHOG MODULATORS | SHH, GLI1, SMO | MMP1 3605/4885GAA 3647/4885MMP12 2386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.